Description - IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.
Total raised: $155M
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2021 | Series B | $155M | - |
Mentions in press and media 10
| Date | Title | Description |
| 12.08.2025 | Вакцина IO Biotech от рака кожи улучшила результаты, но не достигла цели | - |
| 20.12.2024 | IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank | Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025Commitment is part of the European Investment Bank’s strategy to support biotech comp... |
| 06.03.2024 | IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting | - |
| 05.03.2024 | IO Biotech Announces 2023 Fourth-Quarter and Year-End Results | - |
| 07.08.2023 | IO Biotech, Inc. Announces $75 Million Private Placement Financing | Offering includes participation from both new and existing healthcare-dedicated investors Proceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT),... |
| 07.08.2023 | IO Biotech, Inc. Announces $75 Million Private Placement Financing | - |
| 11.05.2023 | IO Biotech Announces 2023 First-Quarter Results | The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma by mid-2023 and to fully enroll the trial by the end of 2023. The Phase 3 trial protocol calls for an interim analysis of overall ... |
| 13.01.2021 | IO Biotech : Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology | COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has rais... |
| 13.01.2021 | IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines | IO Biotech has raised €127 million ($155 million) to fund clinical development of immune-modulating IDO and PD-L1 cancer vaccines. The series B financing round comes months after IO Biotech showed combining its IDO and PD-L1 vaccines with O... |
| 13.01.2021 | IO Biotech Completes €127M Series B Financing | IO Biotech, a Copenhagen, Denmark-based clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, raised €127m in Series B financing. The round was led by ... |